Estrogen Receptor-α Non-Nuclear Signaling Confers Cardioprotection and Is Essential to cGMP-PDE5 Inhibition Efficacy

[1]  B. Katzenellenbogen,et al.  Predominant Role of Nuclear Versus Membrane Estrogen Receptor α in Arterial Protection: Implications for Estrogen Receptor α Modulation in Cardiovascular Prevention/Safety , 2018, Journal of the American Heart Association.

[2]  I. Komuro,et al.  Membrane-Initiated Estrogen Receptor Signaling Mediates Metabolic Homeostasis via Central Activation of Protein Phosphatase 2A , 2018, Diabetes.

[3]  F. Sohler,et al.  Nitric oxide-sensitive guanylyl cyclase stimulation improves experimental heart failure with preserved ejection fraction. , 2018, JCI insight.

[4]  P. Ponikowski,et al.  A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial. , 2017, JACC. Heart failure.

[5]  Daniel Henrion,et al.  Membrane and Nuclear Estrogen Receptor Alpha Actions: From Tissue Specificity to Medical Implications. , 2017, Physiological reviews.

[6]  B. Katzenellenbogen,et al.  Non-nuclear estrogen receptor alpha activation in endothelium reduces cardiac ischemia-reperfusion injury in mice. , 2017, Journal of molecular and cellular cardiology.

[7]  B. Katzenellenbogen,et al.  Design of pathway preferential estrogens that provide beneficial metabolic and vascular effects without stimulating reproductive tissues , 2016, Science Signaling.

[8]  R. Karas,et al.  ER Alpha Rapid Signaling Is Required for Estrogen Induced Proliferation and Migration of Vascular Endothelial Cells , 2016, PloS one.

[9]  E. Murphy,et al.  The Expanding Complexity of Estrogen Receptor Signaling in the Cardiovascular System. , 2016, Circulation research.

[10]  Salil Sharma,et al.  Rescue of Pressure Overload‐Induced Heart Failure by Estrogen Therapy , 2016, Journal of the American Heart Association.

[11]  Sanjiv J. Shah,et al.  Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial. , 2015, JAMA.

[12]  R. D. de Boer,et al.  Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. , 2015, European heart journal.

[13]  M. Nilsson,et al.  Measurement of a Comprehensive Sex Steroid Profile in Rodent Serum by High-Sensitive Gas Chromatography-Tandem Mass Spectrometry. , 2015, Endocrinology.

[14]  Thomas Danner,et al.  Phosphodiesterase 9A Controls Nitric-oxide Independent cGMP and Hypertrophic Heart Disease , 2015, Nature.

[15]  Dong I. Lee,et al.  PDE5 inhibitor efficacy is estrogen dependent in female heart disease. , 2014, The Journal of clinical investigation.

[16]  V. Regitz-Zagrosek,et al.  Cardiomyocyte-specific Estrogen Receptor Alpha Increases Angiogenesis, Lymphangiogenesis and Reduces Fibrosis in the Female Mouse Heart Post-Myocardial Infarction. , 2014, Journal of cell science & therapy.

[17]  Sung Hoon Kim,et al.  Mutation of the palmitoylation site of estrogen receptor α in vivo reveals tissue-specific roles for membrane versus nuclear actions , 2013, Proceedings of the National Academy of Sciences.

[18]  T. McKinsey,et al.  Estrogen regulates histone deacetylases to prevent cardiac hypertrophy , 2013, Molecular biology of the cell.

[19]  P. Chambon,et al.  Prevention of Obesity and Insulin Resistance by Estrogens Requires ERα Activation Function-2 (ERαAF-2), Whereas ERαAF-1 Is Dispensable , 2013, Diabetes.

[20]  V. Roger.  Epidemiology of Heart Failure , 2013, Circulation research.

[21]  J. Arnal,et al.  Tamoxifen elicits atheroprotection through estrogen receptor α AF-1 but does not accelerate reendothelialization. , 2013, The American journal of pathology.

[22]  Takahiro Matsumoto,et al.  Androgen Receptor Promotes Sex-Independent Angiogenesis in Response to Ischemia and Is Required for Activation of Vascular Endothelial Growth Factor Receptor Signaling , 2013, Circulation.

[23]  R. Karas,et al.  Rapid Estrogen Receptor Signaling Is Essential for the Protective Effects of Estrogen Against Vascular Injury , 2012, Circulation.

[24]  F. Fedele,et al.  Chronic Inhibition of cGMP Phosphodiesterase 5A Improves Diabetic Cardiomyopathy: A Randomized, Controlled Clinical Trial Using Magnetic Resonance Imaging With Myocardial Tagging , 2012, Circulation.

[25]  Sang-Eun Lee,et al.  Long-Term Effects of Sildenafil in a Rat Model of Chronic Mitral Regurgitation: Benefits of Ventricular Remodeling and Exercise Capacity , 2012, Circulation.

[26]  P. Chambon,et al.  Activation function 2 (AF2) of estrogen receptor-α is required for the atheroprotective action of estradiol but not to accelerate endothelial healing , 2011, Proceedings of the National Academy of Sciences.

[27]  D. Kass,et al.  Pivotal role of cardiomyocyte TGF-β signaling in the murine pathological response to sustained pressure overload. , 2011, The Journal of clinical investigation.

[28]  B. Frenkel,et al.  Roles of transactivating functions 1 and 2 of estrogen receptor-α in bone , 2011, Proceedings of the National Academy of Sciences.

[29]  R. Arena,et al.  PDE5 Inhibition With Sildenafil Improves Left Ventricular Diastolic Function, Cardiac Geometry, and Clinical Status in Patients With Stable Systolic Heart Failure: Results of a 1-Year, Prospective, Randomized, Placebo-Controlled Study , 2011, Circulation. Heart failure.

[30]  B. Katzenellenbogen,et al.  Non-nuclear estrogen receptor alpha signaling promotes cardiovascular protection but not uterine or breast cancer growth in mice. , 2010, The Journal of clinical investigation.

[31]  R. Karas,et al.  Rapid progress for non-nuclear estrogen receptor signaling. , 2010, The Journal of clinical investigation.

[32]  David Handelsman,et al.  A sex-specific role for androgens in angiogenesis , 2010, The Journal of experimental medicine.

[33]  A. Abbate,et al.  Phosphodiesterase-5 Inhibitor, Tadalafil, Protects Against Myocardial Ischemia/Reperfusion Through Protein-Kinase G–Dependent Generation of Hydrogen Sulfide , 2009, Circulation.

[34]  I. Piña,et al.  Heart failure in women: a need for prospective data. , 2009, Journal of the American College of Cardiology.

[35]  P. Chambon,et al.  The transactivating function-1 of estrogen receptor alpha is dispensable for the vasculoprotective actions of 17 beta-estradiol. , 2009 .

[36]  P. Chambon,et al.  The transactivating function 1 of estrogen receptor α is dispensable for the vasculoprotective actions of 17β-estradiol , 2009, Proceedings of the National Academy of Sciences.

[37]  R. Karas,et al.  Estrogen Attenuates Left Ventricular and Cardiomyocyte Hypertrophy by an Estrogen Receptor–Dependent Pathway That Increases Calcineurin Degradation , 2009, Circulation research.

[38]  D. Kass,et al.  Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload. , 2009, Journal of the American College of Cardiology.

[39]  D. Kass,et al.  Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice. , 2009, The Journal of clinical investigation.

[40]  M. Vannan,et al.  Estrogen inhibits cardiac hypertrophy: role of estrogen receptor-beta to inhibit calcineurin. , 2008, Endocrinology.

[41]  R. Karas,et al.  17 Beta-estradiol differentially affects left ventricular and cardiomyocyte hypertrophy following myocardial infarction and pressure overload. , 2008, Journal of cardiac failure.

[42]  S. Solomon,et al.  Sex Differences in Clinical Characteristics and Prognosis in a Broad Spectrum of Patients With Heart Failure: Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Program , 2007, Circulation.

[43]  S. Cummings,et al.  Comparison of methods to measure low serum estradiol levels in postmenopausal women. , 2006, The Journal of clinical endocrinology and metabolism.

[44]  Vera Regitz-Zagrosek,et al.  Therapeutic implications of the gender-specific aspects of cardiovascular disease , 2006, Nature Reviews Drug Discovery.

[45]  P. Fisher,et al.  Phosphodiesterase-5 Inhibition With Sildenafil Attenuates Cardiomyocyte Apoptosis and Left Ventricular Dysfunction in a Chronic Model of Doxorubicin Cardiotoxicity , 2005, Circulation.

[46]  T. Suda,et al.  Angiopoietin-related growth factor antagonizes obesity and insulin resistance , 2005, Nature Medicine.

[47]  D. Kass,et al.  Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy , 2005, Nature Medicine.

[48]  M. Zaccolo,et al.  cGMP Catabolism by Phosphodiesterase 5A Regulates Cardiac Adrenergic Stimulation by NOS3-Dependent Mechanism , 2004, Circulation research.

[49]  John H. White,et al.  Genome-wide identification of high-affinity estrogen response elements in human and mouse. , 2004, Molecular endocrinology.

[50]  K. Korach,et al.  The Multifaceted Mechanisms of Estradiol and Estrogen Receptor Signaling* , 2001, The Journal of Biological Chemistry.

[51]  P. Chambon,et al.  Estradiol Accelerates Reendothelialization in Mouse Carotid Artery Through Estrogen Receptor-&agr; but Not Estrogen Receptor-&bgr; , 2001, Circulation.

[52]  P. Chambon,et al.  Estradiol Accelerates Reendothelialization in Mouse Carotid Artery Through Estrogen Receptor-α but Not Estrogen Receptor-β , 2001 .

[53]  S. Reis,et al.  Estrogen is associated with improved survival in aging women with congestive heart failure: analysis of the vesnarinone studies. , 2000, Journal of the American College of Cardiology.

[54]  J. Bender,et al.  Human vascular endothelial cells contain membrane binding sites for estradiol, which mediate rapid intracellular signaling. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[55]  G. Koch,et al.  Gender differences in survival in advanced heart failure. Insights from the FIRST study. , 1999, Circulation.

[56]  J. Manson,et al.  Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. , 1996, The New England journal of medicine.

[57]  H. Schnaper,et al.  Estrogen promotes angiogenic activity in human umbilical vein endothelial cells in vitro and in a murine model. , 1995, Circulation.

[58]  F. Grodstein,et al.  Cardioprotective effect of hormone replacement therapy Is not due to a selection bias , 1994, BMJ.

[59]  Robert Dolejší,et al.  The First Study , 1939 .